.jpg)
In a report released yesterday, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), with a price target of $205. The company’s shares closed yesterday at $179.90, close to its 52-week high of $184.
According to TipRanks.com, Samimy is a 4-star analyst with an average return of 10.8% and a 52.4% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Cara Therapeutics, and TherapeuticsMD.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $200.91 average price target, implying an 11.7% upside from current levels. In a report issued on July 24, Piper Jaffray also reiterated a Buy rating on the stock with a $210 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $184 and a one-year low of $128.58. Currently, Jazz Pharmaceuticals has an average volume of 570K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
